Abstract
In recent years, a progressive increase in age-related disorders could be observed in most western countries, among which Alzheimer's disease (AD) is one of the most challenging. BACE1 could be seen as an attractive target to develop disease-modifying compounds, and in this context, a new series of hybrid molecules was designed and synthesized, based on a previously identified multitarget lead compound. In particular, the amino side chain was appropriately modified to fit BACE1 as additional target. In vitro testing results pointed out compound 8 (IC50=2.49±0.08 μM), bearing the bulky bis(4-fluorophenyl)methyl)piperazine substituent, as the most potent BACE1 inhibitor of the series.
Keywords:
AChE; Alzheimer’s disease; BACE1; Drug discovery; Indanone.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylcholinesterase / chemistry*
-
Acetylcholinesterase / metabolism
-
Amines / chemistry
-
Amyloid Precursor Protein Secretases / antagonists & inhibitors*
-
Amyloid Precursor Protein Secretases / metabolism
-
Aspartic Acid Endopeptidases / antagonists & inhibitors*
-
Aspartic Acid Endopeptidases / metabolism
-
Binding Sites
-
Cholinesterase Inhibitors / chemical synthesis
-
Cholinesterase Inhibitors / chemistry*
-
Cholinesterase Inhibitors / metabolism
-
Drug Design
-
Humans
-
Indans / chemical synthesis
-
Indans / chemistry*
-
Indans / metabolism
-
Molecular Docking Simulation
-
Protease Inhibitors / chemical synthesis
-
Protease Inhibitors / chemistry*
-
Protease Inhibitors / metabolism
-
Protein Binding
-
Protein Structure, Tertiary
-
Structure-Activity Relationship
Substances
-
Amines
-
Cholinesterase Inhibitors
-
Indans
-
Protease Inhibitors
-
indacrinone
-
Acetylcholinesterase
-
Amyloid Precursor Protein Secretases
-
Aspartic Acid Endopeptidases
-
BACE1 protein, human